Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore ...

Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...

California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and multi-target research ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

A clinical-stage biotech company based in Redwood City, California, developing tissue-restorative biologics for chronic ...

Biotechnology startup Juvena Therapeutics Inc. has raised $41 million in new venture-capital funding to advance technology that could expand the range of treatments for chronic conditions and ...

Obesity-drug makers have signed deals that could be worth $812 million to a South San Francisco company and more than $650 million to a Redwood City company. How a $200K UC Berkeley grant could launch ...

REDWOOD CITY, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle ...